Homepage > Company > Media > Pharma News > 2019 > No provisions in USMCA to change U.S. pharmaceutical patent laws: Lighthizer

No provisions in USMCA to change U.S. pharmaceutical patent laws: Lighthizer

(Reuters) - The United States-Mexico-Canada Agreement has no provisions that would force changes to U.S. laws with respect to pharmaceutical companies, U.S. Trade Representative Robert Lighthizer said on Tuesday.

“To the extent that a member (of Congress) thinks anything in here will stop you from changing laws, then we have to correct that,” Lighthizer said at a hearing of the Senate Finance Committee.

JUNE 18, 2019

https://www.reuters.com/

Read also

EC approves AstraZeneca’s Fasenra for EGPA treatment

The European Commission (EC) has approved AstraZeneca‘s Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangii...

Genprex reports positive preclinical gene therapy data

Genprex, Inc., a clinical-stage gene therapy company, announced positive preclinical results for its lead drug candidate, Reqorsa® (quratusugene ozeplasmid) Gene Therapy, at the recent EORTC-...

Astellas withdraws Europe ACP application for AMD treatment

Astellas Pharma has announced the withdrawal of its marketing authorisation application for IZERVAY (avacincaptad pegol, ACP) intravitreal solution to treat geographic atrophy (GA) sec...

New report demands greater understanding of the impact of change on academia

Digital Science, a technology company serving stakeholders across the research ecosystem, is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having ...